{"name":"CuraSen Therapeutics, Inc.","slug":"curasen-therapeutics-inc","ticker":"","exchange":"","domain":"curasen.com","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"CST-3056","genericName":"CST-3056","slug":"cst-3056","indication":"Relapsed or refractory T-cell lymphoma","status":"phase_2"}]}],"pipeline":[{"name":"CST-3056","genericName":"CST-3056","slug":"cst-3056","phase":"phase_2","mechanism":"CST-3056 is a small molecule inhibitor of the CDK9 enzyme.","indications":["Relapsed or refractory T-cell lymphoma"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi3gJBVV95cUxQcG0tTThJR1YtYWZQeEZUMVdvQ3FPd1RfSXh2cU1LWTM2Y0JoN3FsaDEwYW1ZMmdYRTg1WjNfMkZobFNxdzhVb19JaFZQY2dlb0tnbmhBOXUyWWdxMGROQU1MQmhFVUlicF96cnFtODY1MUZHTHU1RVRLOGFIaHh4eFEwMzhzMmlua09OeWdxMFZzaHRPWENwbWtCVUVXSGEtUWdqRkVCRFJwUTcxdzFSU0Z2N3NrbnVyTUZlbHE0QmsxYWJsMGJ6cDVEMEhlR3hSYmlZT1BoemVJRkw0bmVkMHN1NEVJTEtJWEYyUmRqRnBzbGs2UVdpbTFwUFUtb0IxY25GWk5GdWNsRXZ5RkRBbWt5VDJvbHlXeE9hTTAtQl93MEVxWk5aVDE0UWRrcXEzQngxeWU5ME43OUNfR1ZPMFlMalhSY0JRNW1SNGJ0dm16UWdhZngta3g4Ukx4Zw?oc=5","date":"2025-11-10","type":"trial","source":"businesswire.com","summary":"CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056) at the 2025 American Autonomic Society (AAS) International Symposium - business","headline":"CuraSen Therapeutics Presents Positive Phase 1 Safety, Pharmacokinetics and Pharmacodynamics Data with CuraAX (CST-3056)","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMi7wFBVV95cUxOenY1emdtdmN5b0NRblBfaVk4WUtCZUZuTmVwWlN4ZXNTdDFpdXkyUEJtSm8wb2ROWlBHVzBiS2hQRUQ5dkJhcVhuV2xsMGVGb09qZ3JYNlEtMGlEczJZWkF0WkE3Q2gtVVExWHFpZEtwT1p3ZGlsQklZTEMydm80ZWRfV3ljYXBha01rZHlSNE51Z2VsX3VzN1ZET1BmSHhGOUpnSGR2WVhhZHFvSDJGWW95VzVjVG1FRnBGbzhUa0NDSWlvWjlYWUVJdEROeUVfNHhSWHJZOFA1M0tlTkRhY0t3T1ZraXBpX0s4dzNUZw?oc=5","date":"2025-02-20","type":"trial","source":"businesswire.com","summary":"CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial - businesswire.com","headline":"CuraSen Therapeutics Announces First Subject Treated with CuraAX (CST-3056) in a Phase 1 Clinical Trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiygFBVV95cUxNSUwtUWlubkloR3dfMTRYZ0VBcmlCYjdvVVVBWk5oa1ZXUU5YOVZoTXUtdGhZSVZsUWkyajY4a1BrSW5GVlN2aTBpQ0phcV95bzhSblFjYjlka180R1hiS2hPck1LblpUZEtTYWZfVUZJUEhvWV9nOWJWOEFXZXNTZ291c1U4M0Fqd0RHcUE1UnhpcF9vZnZwaHNCV0k5dHVpWDVUSEM2ajFhYVoyVjZmYlE0TGhhM1R5a2R2YVBHWkh6UE94SUFJeTNn?oc=5","date":"2024-10-17","type":"pipeline","source":"The Business Journals","summary":"Longtime biotech entrepreneur, exec named CEO of CuraSen Therapeutics - Bizwomen - The Business Journals","headline":"Longtime biotech entrepreneur, exec named CEO of CuraSen Therapeutics - Bizwomen","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxON2tMY0EzZkwwTXZvUjFxUDg5N1Y5cW11V0w0Z080UWFyV0dhU3JMVVpXRGx1MXJST0xEc0hOWmhscDdLZXdReDEzcW5hWW04MUFncnVRVmxLV19wc2RmNGxXLW9Mbk9TUlZsTDdZWFRaRkF4enFRN0I3aXUxdm8taUJLdUlxOHo1ZC1nZnQwVnJ4UjBjckNvbjloTWdBUC1sU0pqMFpjRm0wSnVqQVYtbUY3ZGtxS0U3QmV2eGlKR3pPMmRMRTJfTW04V00?oc=5","date":"2024-10-15","type":"pipeline","source":"businesswire.com","summary":"CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer - businesswire.com","headline":"CuraSen Therapeutics Appoints Kathleen Sereda Glaub Chief Executive Officer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOcWZNdkx5S3pseEljTkJjZUNmTGlFd09oWkJYQ1BHSG95cVhHN0xJSGVoSnZTc0VnYUg1RUh1Ym9qSDF5U3o0NEplU204YjZuX3prQzhHTXY3ZHk4TlBicndSQ2t4TnlHNnBCMHZuc3g1ZmtRV0VhZ21RRWdmYjFpVVp5NVhVV1BMWHR0VUMwdTJiNTZ3MHJiZTNkX1FSeldKTVRSNkRDTWItWU0?oc=5","date":"2024-10-15","type":"pipeline","source":"The Business Journals","summary":"Genenexer who sold two startups for $1 billion each named CEO of CuraSen Therapeutics - The Business Journals","headline":"Genenexer who sold two startups for $1 billion each named CEO of CuraSen Therapeutics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipgFBVV95cUxOa2FuaTJCR1d0NkVQbmkyUHIta0IxbHphZDZkMU1VVHZXMDdhU005dHNqYVVyRmZUNjRPS19LUWYzXzZmZGlDcDQyOWhhZ0o1Mm13OU52Mk1IcWctYmliSUhrZ1FvUDdZVlQ3Z0RiVG96UUpENjVDakV4dVpJcTZrbnpsdENRZkhyNENYVXcydWJtSnJlRTNLamhBcWhfT1ppZldHelB3?oc=5","date":"2024-07-03","type":"pipeline","source":"World Business Outlook","summary":"Acurex Biosciences welcomes Dr. Robert Booth to its Board of Directors - World Business Outlook","headline":"Acurex Biosciences welcomes Dr. Robert Booth to its Board of Directors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxPQTk1RjhIcHNLLWhTYVRZVmtIRUY0TjhlWG9lTmE1bERLbXZRTjlZa1k1c2xZY0hTUXV3bVhia19MZGRLM3NhVEFoMkkwUU8wdjNEeHVvRW9Ua25VeGRKQWlUbHJhMEFyeDhVLS1fem13QTRvTElTakFMRHlGWkR0amNsYm9QVFBHeUxR?oc=5","date":"2024-05-10","type":"trial","source":"openPR.com","summary":"Dementia Market 2032: Epidemiology Data, Pipeline - openPR.com","headline":"Dementia Market 2032: Epidemiology Data, Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirAJBVV95cUxNeDdqQ05ZcVhNR3FNSGg0TnR6UHJhckRJTnhPbmdkV0xUZWhiRjdmZUREdnlhbjRsZTJVaEdwUHVBMmp5N3lMckZqVVd2ZkxWX3pYOUpqdTUwUGlFRGxpcndPd1JpeTZ1dUJEbm16RlRMTmNCdk5jODFCNG1QOFRzNi1vVm9oMUhoVFJlSkc3UlI1cVdsMWxxdzBGeTFxN2F1eVVJbURHQU04SEdRSzVsS3k1UFVLc2dmQzJyRko4RlVrNW9jTTVBeXhObWhFUTRJTEtKTy1wQVJvTGpvVklqNm5jQU9qdkNSbWJKc0FHdFZlcXMtdHotdUt6ZG9hcEluWEN6YWx5cFg4bTh2TkdJRFhMWjBTMkc0c1pNX2l1Y1daU3BicnJLRWtBdjA?oc=5","date":"2023-04-19","type":"trial","source":"prnewswire.com","summary":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Working in the Domain | DelveInsight - prnewswire.com","headline":"Parkinson's Disease Clinical Trial Pipeline Space Brims With Novel Emerging Therapies with Over 120 Key Companies Workin","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxNV3dKT1U5b0tUdnlaV2dkNUhVWHpRa2Juc0pET1RBQjNyYnY3Rk9wRk81TjZ1Ti0ySDdhT2ZsbjFjNkwxV0NSbkhveWdlei1FeEVqcDlLT0M5aXo2MzVtOTBxZk9kaTRzQ0pUSllhMzh3dHI4YzdPMkhlUzlGYTE0QnlndndTQ3BkckZVS1ZadVRtc3RUVGlPeTQ5dl9JZlpSYTFjWDUxRTR4OHotcW5jRVJn?oc=5","date":"2018-10-17","type":"pipeline","source":"The Business Journals","summary":"They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more - The Business Journals","headline":"They tackled chronic cough. Now with $54.5 million, this duo is targeting Alzheimer's and more","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}